HIV disease progression compared by linkage status in Rwanda and Zambia

por Kilembe, W, Dinh, C, Lakhi, S, Karita, E, Bayingana, R, Price, M, Allen, S, Hunter, E
Publicado 2012

P14-13. Long-term follow-up of study participants in HIV prophylactic vaccine clinical trials in Africa

por Schmidt, C, Jaoko, W, Kaleebu, P, Karita, E, Lehrman, Allen, S, Dally, L, Smith, C, Fast, PE
Publicado 2009

Training trial staff in the use of a mixed method assessment of understanding tool in HIV vaccine trials

por Mbogua, J, Mebrahtu, T, Lindegger, G, Sabrina, W, Anzala, O, Mutua, G, Mpendo, J, Karita, E, Singh, S
Publicado 2012

P20-14. Co- and superinfection of partners in a cohort of couples previously infected by genotypically different viruses in Kigali

por Manigart, O, Kraft, C, Makombe, N, Kimenyi, P, Flandin, J, Karita, E, Boeras, D, Allen, S, Hunter, E
Publicado 2009

Sexual behavior among volunteers enrolled in a Phase I HIV vaccine trial: experience of Projet San Francisco in Kigali, Rwanda

por Mukamuyango, J, Karita, E, Bayingana, R, Nyombayire, J, Ingabire, R, Allen, S, Tichacek, A, Fast, P, Price, M, Schmidt, C
Publicado 2012

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients

por Karita, E, Kayitenkore, K, Bayingana, R, Sebahungu, F, Bizimana, J, Grabowski, K, Tichacek, A, Schmidt, C, Fast, P, Hunter, E, Allen, S
Publicado 2009

Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned

por Bayingana, R, Nanvubya, A, Karita, E, Nyombayire, J, Ingabire, R, Chinyenze, K, Lehrman, J, Schimidt, C, Hannaman, D, Allen, S, Fast, P
Publicado 2012

Tolerability and acceptability of electroporation during a Phase 1 vaccine trial at two sites in Uganda and Rwanda

por Mpendo, J, Bayingana, R, Nanvubya, A, Karita, E, Ssetaala, A, Kiwanuka, N, Lehrman, J, Schmidt, C, Hannaman, D, Allen, S, Fast, P
Publicado 2012

Sequential exposure to specific antibody escape mutations may program neutralization breadth during subtype A HIV-1 infection

por Murphy, MK, Yue, L, Pan, R, Boliar, S, Sethi, A, Karita, E, Allen, SA, Cormier, E, Robinson, JE, Gnanakaran, S, Hunter, E, Kong, X, Derdeyn, CA
Publicado 2012

Dopaminergic Drug Effects on Probability Weighting during Risky Decision Making

por Ojala, Karita E., Janssen, Lieneke K., Hashemi, Mahur M., Timmer, Monique H. M., Geurts, Dirk E. M., ter Huurne, Niels P., Cools, Roshan, Sescousse, Guillaume
Publicado 2018

P06-08. Building an African HIV preventive trial network

por Price, MA, Allen, S, Anzala, O, Bekker, L, Gilmour, J, Kaleebu, P, Kamali, A, Karita, E, Lakhi, S, Latka, M, Twesigye, R, Sanders, EJ, Amornkul, P, Stevens, G, Thomson, H
Publicado 2009

Developing standards of care for HIV prevention research in developing countries – a case study of ten research centers in Eastern and Southern Africa

por Ngongo, BP, Priddy, F, Park, H, Bender, B, Fast, P, Anzala, O, Mutua, G, Ruzagira, E, Kamali, A, Karita, E, Mugo, P, Chomba, E, Bekker, L, Roux, S, Nanvubya, A, Mebrahtu, T
Publicado 2012

A35 Viral evolution and innate immune responses during acute HIV-1 infection and their association with disease pathogenesis

por Hassan, A.S., Hare, J., Kamini, G., Yindom, L.M., Kamali, A., Karita, E., Kilemba, W., Price, M.A., Borrow, P., Bjorkman, P., Albert, J., Kaleebu, P., Allan, S., Fast, P., Hunter, E., Gilmour, J., Ndung’u, T., Rowland-Jones, S., Sanders, E.J., Esbjornsson, J.
Publicado 2017